pimagedine has been researched along with Cataract in 19 studies
pimagedine: diamine oxidase & nitric oxide synthase inhibitor; an advanced glycosylation end product inhibitor; used in the treatment of diabetic complications; structure
aminoguanidine : A one-carbon compound whose unique structure renders it capable of acting as a derivative of hydrazine, guanidine or formamide.
Cataract: Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to investigate whether curcumin and aminoguanidine (AG) prevent selenium-induced cataractogenesis in vitro." | 7.75 | Anti-cataractogenic effect of curcumin and aminoguanidine against selenium-induced oxidative stress in the eye lens of Wistar rat pups: An in vitro study using isolated lens. ( Arumugam, M; Beulaja, S; Chindhu, S; Manikandan, R; Mariammal, K; Sudhandiran, G; Thiagarajan, R, 2009) |
| "To investigate the effect of carnosine (CA), aminoguanidine (AG), and aspirin (ASA) drops, all inhibitors of glycation, on the development of diabetic cataract in rat." | 7.74 | Effect of carnosine, aminoguanidine, and aspirin drops on the prevention of cataracts in diabetic rats. ( Ding, Z; Guo, Y; Ha, W; Harding, JJ; Yan, H; Zhang, J, 2008) |
| "We examined the ability of a pyridoxal-aminoguanidine adduct with both antiglycation and antioxidant activities in vitro to protect against neuropathy and cataract in streptozotocin-diabetic rats and compared the result with that of aminoguanidine." | 7.72 | Pyridoxal-aminoguanidine adduct is more effective than aminoguanidine in preventing neuropathy and cataract in diabetic rats. ( Chen, AS; Kamei, A; Miwa, I; Sugiura, M; Taguchi, T; Wakasugi, Y; Wang, MW, 2004) |
| "It is well known that m-calpain, a ubiquitous calpain, is involved in cataract formation in rodent lens." | 7.71 | Comparison of Lp82- and m-calpain-mediated proteolysis during cataractogenesis in Shumiya cataract rat (SCR). ( Hayashi, M; Inomata, M; Ito, Y; Kawashima, S; Matsubara, Y; Shumiya, S; Takehana, M, 2002) |
| "The aim of this study was to investigate whether curcumin and aminoguanidine (AG) prevent selenium-induced cataractogenesis in vitro." | 3.75 | Anti-cataractogenic effect of curcumin and aminoguanidine against selenium-induced oxidative stress in the eye lens of Wistar rat pups: An in vitro study using isolated lens. ( Arumugam, M; Beulaja, S; Chindhu, S; Manikandan, R; Mariammal, K; Sudhandiran, G; Thiagarajan, R, 2009) |
| "To investigate the effect of carnosine (CA), aminoguanidine (AG), and aspirin (ASA) drops, all inhibitors of glycation, on the development of diabetic cataract in rat." | 3.74 | Effect of carnosine, aminoguanidine, and aspirin drops on the prevention of cataracts in diabetic rats. ( Ding, Z; Guo, Y; Ha, W; Harding, JJ; Yan, H; Zhang, J, 2008) |
| "We examined the ability of a pyridoxal-aminoguanidine adduct with both antiglycation and antioxidant activities in vitro to protect against neuropathy and cataract in streptozotocin-diabetic rats and compared the result with that of aminoguanidine." | 3.72 | Pyridoxal-aminoguanidine adduct is more effective than aminoguanidine in preventing neuropathy and cataract in diabetic rats. ( Chen, AS; Kamei, A; Miwa, I; Sugiura, M; Taguchi, T; Wakasugi, Y; Wang, MW, 2004) |
| "It is well known that m-calpain, a ubiquitous calpain, is involved in cataract formation in rodent lens." | 3.71 | Comparison of Lp82- and m-calpain-mediated proteolysis during cataractogenesis in Shumiya cataract rat (SCR). ( Hayashi, M; Inomata, M; Ito, Y; Kawashima, S; Matsubara, Y; Shumiya, S; Takehana, M, 2002) |
| "Subcutaneous injection of sodium selenite was used to induce cataracts in rats, with or without pretreatment with NOS inhibitors." | 3.71 | Nitric oxide participates in cataract development in selenite-treated rats. ( Hori, R; Ito, Y; Nabekura, T; Nakao, M; Takeda, M; Terao, M; Tomohiro, M, 2001) |
| "Cataract formation occurred after 13 weeks in diabetic animals compared with 17 weeks for those treated with aminoguanidine, and 16 weeks for those treated with probucol (p < 0." | 3.70 | Effects of inhibition of glycation and oxidative stress on the development of cataract and retinal vessel abnormalities in diabetic rats. ( Agardh, C; Agardh, E; Hultberg, B, 2000) |
| "To study the effects of an aldose reductase inhibitor (ARI-509, Wyeth-Ayerst, Princeton, NJ) and aminoguanidine (AMG), agents that have been reported to prevent or delay diabetic retinopathy, on retinal vascular abnormalities and the immunocytochemical expression in the retina of vascular endothelial growth factor (VEGF) in rats maintained for up to 2 years on a 50% galactose diet." | 3.69 | An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia. ( Amin, R; Frank, RN; Hohman, TC; Kennedy, A, 1997) |
| "Cataract was observed in all six of the surviving rats in Groups 2 and 4, and in one of 6 surviving rats in group 3." | 1.31 | Effects of aminoguanidine and tolrestat on the development of ocular and renal structural changes in experimental diabetic rats. ( Azal, O; Baydar, A; Cakir, B; Corakçi, A; Güler, S; Kutlu, M; Yönem, A, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (21.05) | 18.2507 |
| 2000's | 15 (78.95) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yan, H | 1 |
| Guo, Y | 1 |
| Zhang, J | 1 |
| Ding, Z | 1 |
| Ha, W | 1 |
| Harding, JJ | 1 |
| Manikandan, R | 1 |
| Thiagarajan, R | 1 |
| Beulaja, S | 1 |
| Chindhu, S | 1 |
| Mariammal, K | 1 |
| Sudhandiran, G | 1 |
| Arumugam, M | 1 |
| Kawakami, M | 1 |
| Kuroki, M | 1 |
| Nabekura, T | 3 |
| Koizumi, Y | 1 |
| Nakao, M | 2 |
| Tomohiro, M | 3 |
| Inomata, M | 4 |
| Ito, Y | 8 |
| Hayashi, M | 3 |
| Matsubara, Y | 1 |
| Takehana, M | 1 |
| Kawashima, S | 3 |
| Shumiya, S | 3 |
| Kitagawa, S | 1 |
| Chen, AS | 1 |
| Taguchi, T | 1 |
| Sugiura, M | 1 |
| Wakasugi, Y | 1 |
| Kamei, A | 1 |
| Wang, MW | 1 |
| Miwa, I | 1 |
| Nagai, N | 2 |
| Fukuhata, T | 1 |
| Joon, TL | 1 |
| Foo, K | 1 |
| Panagiotopoulos, S | 1 |
| Jerums, G | 1 |
| Taylor, HR | 1 |
| Stevens, A | 1 |
| Swamy-Mruthinti, S | 1 |
| Green, K | 1 |
| Abraham, EC | 1 |
| Frank, RN | 1 |
| Amin, R | 1 |
| Kennedy, A | 1 |
| Hohman, TC | 1 |
| Agardh, E | 1 |
| Hultberg, B | 1 |
| Agardh, C | 1 |
| Stitt, AW | 1 |
| Takeda, M | 1 |
| Terao, M | 1 |
| Hori, R | 1 |
| Azal, O | 1 |
| Yönem, A | 1 |
| Güler, S | 1 |
| Cakir, B | 1 |
| Baydar, A | 1 |
| Corakçi, A | 1 |
| Kutlu, M | 1 |
2 reviews available for pimagedine and Cataract
| Article | Year |
|---|---|
[Aminoguanidine and other AGE inhibitors].
Topics: Amides; Animals; Arteriosclerosis; Cardiovascular Diseases; Cataract; Clinical Trials as Topic; Diab | 2002 |
Advanced glycation: an important pathological event in diabetic and age related ocular disease.
Topics: Aging; Animals; Cataract; Diabetic Retinopathy; Enzyme Inhibitors; Glaucoma; Glycation End Products, | 2001 |
17 other studies available for pimagedine and Cataract
| Article | Year |
|---|---|
Effect of carnosine, aminoguanidine, and aspirin drops on the prevention of cataracts in diabetic rats.
Topics: Animals; Aspirin; Blood Glucose; Body Weight; Carnosine; Cataract; Cornea; Diabetes Mellitus, Experi | 2008 |
Anti-cataractogenic effect of curcumin and aminoguanidine against selenium-induced oxidative stress in the eye lens of Wistar rat pups: An in vitro study using isolated lens.
Topics: Animals; Base Sequence; Catalase; Cataract; Curcumin; DNA Primers; Glutathione; Glutathione Peroxida | 2009 |
Delay of cataract development in hereditary cataract UPL rats by disulfiram and aminoguanidine.
Topics: Aging; Animals; Antioxidants; Calcium; Cataract; Crystallins; Disulfiram; Enzyme Inhibitors; Eye Dis | 2003 |
Comparison of Lp82- and m-calpain-mediated proteolysis during cataractogenesis in Shumiya cataract rat (SCR).
Topics: Aging; alpha-Crystallin A Chain; Animals; Antibodies; Blotting, Western; Calpain; Case-Control Studi | 2002 |
Changes in plasma membrane Ca2+ -ATPase expression and ATP content in lenses of hereditary cataract UPL rats.
Topics: Adenosine Triphosphate; Animals; Calcium-Transporting ATPases; Cataract; Cell Membrane; Disease Mode | 2004 |
Pyridoxal-aminoguanidine adduct is more effective than aminoguanidine in preventing neuropathy and cataract in diabetic rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Cataract; Deoxyguanosine; Diabetes Mellitus, Experimental; Dia | 2004 |
Effect of magnesium deficiency on intracellular ATP levels in human lens epithelial cells.
Topics: Adenosine Triphosphate; Calcium-Transporting ATPases; Cataract; Cell Line; Chelating Agents; Disease | 2007 |
Adverse effects of excessive nitric oxide on cytochrome c oxidase in lenses of hereditary cataract UPL rats.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Cataract; Disease Models, Animal; Disulfiram; | 2007 |
In vivo assessment of an animal model of diabetic cataract: medical intervention studies.
Topics: Aldehyde Reductase; Animals; Antioxidants; Cataract; Diabetes Mellitus, Experimental; Disease Models | 1994 |
The effectiveness of putative anti-cataract agents in the prevention of protein glycation.
Topics: Animals; Aspirin; Cataract; Cattle; Eye Proteins; Glycation End Products, Advanced; Glycosylation; G | 1995 |
Inhibition of cataracts in moderately diabetic rats by aminoguanidine.
Topics: Animals; Cataract; Diabetes Mellitus, Experimental; Disease Progression; Glycation End Products, Adv | 1996 |
An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia.
Topics: Aldehyde Reductase; Animals; Cataract; Diabetic Retinopathy; Endothelial Growth Factors; Enzyme Inhi | 1997 |
Effects of inhibition of glycation and oxidative stress on the development of cataract and retinal vessel abnormalities in diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Cataract; Cysteine; Diabetes Mellitus, Experimental; Diabetic R | 2000 |
Aminoguanidine-treatment results in the inhibition of lens opacification and calpain-mediated proteolysis in Shumiya cataract rats (SCR).
Topics: Animals; Blotting, Western; Calcium; Calpain; Cataract; Crystallins; Disease Models, Animal; Guanidi | 2000 |
Nitric oxide participates in cataract development in selenite-treated rats.
Topics: Animals; Blotting, Western; Calcium; Cataract; Chromatography, High Pressure Liquid; Enzyme Inhibito | 2001 |
Involvement of inducible nitric oxide synthase in cataract formation in Shumiya cataract rat (SCR).
Topics: Animals; Blotting, Western; Calcium; Calpain; Cataract; Enzyme Inhibitors; Guanidines; Image Process | 2001 |
Effects of aminoguanidine and tolrestat on the development of ocular and renal structural changes in experimental diabetic rats.
Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Cataract; Diabetes Mellitus, Experimental; | 2002 |